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Current clinical efficacy of chloroquine for the
treatment of Plasmodium falciparum infections in
urban Dar es Salaam, United Republic of Tanzania
Z. Premji,1 C. Makwaya,2 & J.N. Minjas3
Reported is the use of a 14-day WHO protocol, which takes into account the clinical, parasitological and
haematological responses to antimalarial drugs, to determine the efficacy of chloroquine in the treatment of
uncomplicated malaria in young children (n = 200) in urban Dar es Salaam. Chloroquine failure was found in 43% of
the children. Of these, 12.5% were considered to be early treatment failures and were given a single dose of
sulfadoxine–pyrimethamine. Fever subsided in all children treated with sulfadoxine–pyrimethamine and there were no
parasitological failures. In addition, children treated with sulfadoxine–pyrimethamine because of early treatment
failure with chloroquine had better haematological recovery than the chloroquine-sensitive group. It is concluded that
chloroquine can no longer be considered an effective therapy for P. falciparum malaria in young children in Dar es
Salaam.
Voir page 743 le re´sume´ en franc¸ais. En la pa´gina 744 figura un resumen en espan˜ol.
Introduction
Since the emergence of chloroquine-resistant falci-
parum malaria in the United Republic of Tanzania (1)
there has been an upward trend in the frequency and
degree of the resistance (2). Nevertheless, chloro-
quine remains the official first-line antimalarial drug
in the United Republic of Tanzania, while neighbour-
ing Malawi and Kenya have already replaced
chloroquine with sulfadoxine–pyrimethamine as
first-line treatment for nonsevere malaria in young
children (3).
Antimalarial drug resistance has previously
been assessed mainly by determining parasite
clearance in asymptomatic children (4). However,
resistance rates based on parasite clearance only are
inadequate for making decisions about drug efficacy:
evidence of a lack of clinical response is also needed.
A 14-day protocol which takes into account both
symptomatic resolution and parasite clearance has
therefore recently been proposed by WHO (5).
This study reports our experience with the
protocol and the status of Plasmodium falciparum
sensitivity to chloroquine in Dar es Salaam.
Materials and methods
Study site
The study was carried out at Temeke district hospital
during the peak malaria transmission season in 1997
(May–August). The hospital serves a population of
about 800 000 people in Temeke district, one of the
three administrative districts within the city of Dar es
Salaam.
Study procedure
The WHO protocol for assessing the therapeutic
efficacy of antimalarial drugs against uncomplicated
falciparum malaria in areas with intense transmission
(5) was followed. Children aged 6–60 months who
were attending the outpatient department of the
hospital were recruited. Inclusion criteria were as
specified in the protocol with the exception that
children with a history of fever in the preceding
12 hours but without raised axillary temperature at
attendance were also enrolled.
Children were examined clinically to exclude
other causes of fever, their axillary temperatures and
weights were measured, blood slides to evaluate
parasitaemia were prepared, and packed cell volumes
were also determined. Those children meeting the
parasite density criteria (2000 asexual parasites per ml)
were enrolled and oral chloroquine treatment was
administered under supervision.
Follow-up
All children recruited were seen at the hospital again
on day 1 and day 2 for clinical examination and
chloroquine administration. Subsequently they were
seen on day 3 and day 7 for preparation of blood
slides, and those who were treatment failures were
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given a single dose of sulfadoxine–pyrimethamine.
The children were again seen on day 14, when in
addition to the clinical examination and blood slide
preparation a repeat determination of packed cell
volume was carried out.
Drug treatment
All children were treated with chloroquine tablets
(150 mg of chloroquine phosphate, Helm Pharma-
ceuticals GmbH, Hamburg, Germany) at a dosage of
25 mg/kg body weight, given as 10 mg/kg body
weight on days 0 and 1 and 5 mg/kg body weight on
day 2. In all cases of chloroquine treatment failure,
sulfadoxine–pyrimethamine (Fansidar1, Hoffmann-
La Roche, Basel, Switzerland) (1.25mg pyrimetha-
mine/kg body weight) was given. In addition, for
ethical reasons, paracetamol tablets were also given
for the first 2 days and during the follow-up if fever
was documented.
Laboratory examination
Thick and thin blood smears were made on the same
slide and stained with 5% Giemsa at pH 7.2 for
20 min. Parasite density was assessed by counting the
number of asexual parasites per 200 leukocytes in the
thick smear. Parasite numbers were converted to a
count per ml by assuming a standard leukocyte count
of 8000 per ml. Species were confirmed by examining
the thin film. Blood for packed cell volume
determination was centrifuged using the standard
haematocrit centrifuge (UL Adams Autocrit Cen-
trifuge, USA) and the percentage of packed red cells
in the plasma was recorded.
Classification of therapeutic responses
Three categories of therapeutic responses were
defined.
. Early treatment failure. If the patient developed
one of the following during the first three days of
follow-up:
– danger signs or severe malaria on day 1, 2 or 3 in
the presence of parasitaemia;
– axillary temperature of5 37.5 oC on day 2 with
parasitaemia greater than that on day 0;
– axillary temperature of 5 37.5 oC on day 3 in
the presence of parasitaemia;
– parasitaemia on day 3 5 25% of the count of
day 0.
. Late treatment failure. If the patient developed
one of the following during the follow-up period
from day 4 to day 14:
– danger signs or severe malaria in the presence
of parasitaemia on any day from day 4 to day 14,
if none of the criteria of early treatment failure
have previously been met;
– axillary temperature5 37.5 oC in the presence
of parasitaemia from day 4 to day 14, if none of
the criteria of early treatment failure have
previously been met.
. Adequate clinical response. If the patient showed
one of the following during the follow-up period,
i.e. up to 14 days.
– absence of parasitaemia on day 14 irrespective
of axillary temperature, if none of the criteria of
early or late treatment failure have previously
been met;
– axillary temperature < 37.5 oC irrespective of
the presence of parasitaemia, if none of the
criteria for early or late treatment failure have
previously been met.
Results
A total of 608 children were screened in the
outpatient department and, of these, 486 (80%) had
parasitaemia. However, only 259 children (53%)
fulfilled the criteria for enrolment. One child
developed symptoms of severe malaria after the first
dose of chloroquine and was therefore excluded
from the study. During the follow-up, 58 children
dropped out. A complete set of data was thus
available for 200 children. Baseline clinical and
laboratory characteristics are shown in Table 1.
Clinical response to chloroquine
A total of 114 (57%) children had adequate clinical
response as well as parasite clearance by day 14 and
had therefore been successfully treated with chlor-
oquine. The remaining 86 (43%) children exhibited
chloroquine treatment failure. Early treatment failure
was recorded in 25 children (12.5% (95% confidence
interval (CI), 7.9–17.1)) and late treatment failure was
recorded in 61 children (30.5% (95% CI, 24.1–36.9)).
Of the 61 children with late treatment failure, 28
(45.9%) had been registered as such by day 7, while
the remaining 33 (54.1%) were registered on day 14.
Table 2 shows the fever and parasitaemia profiles of
the children with treatment failure.
Initial parasitaemia and therapeutic
response
The outcome of patients with low parasitaemia
(<5000 asexual parasites per ml) at recruitment was
compared with those whose recruitment parasitae-
Table 1. Baseline characteristics of the study patients (n = 200)
Mean age + SD (months) 28.2 + 16.5
Weight + SD (kg) 11.0 + 3.2; (6–20)a
No. of reported antimalarial treatments 30; 15 b
in preceding week
No. with a history of fever in preceding 12 hours 199; 99.5
No. with axillary temperature 5 37.5 oC 154; 77
Geometric mean parasitaemia density (per ml) 6 404 (2 000–152 000)
Mean packed cell volume + SD 27.5% + 5.1
a Figures in parentheses are the range.
b Figures in italics are percentages.
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mia was 55000 asexual parasites per ml. The failure
rate was 37.2% for children whose parasite count was
low, while for those whose parasite count was high
the failure rate was 50.6%. The difference in failure
rates between those with low and high parasitaemias
at recruitment was not significant. The rate ratio was
1.27 (95% CI, 0.98–1.64)
Clinical response to sulfadoxine–
pyrimethamine
Parasitaemia cleared in all children treated with
sulfadoxine–pyrimethamine after treatment failure
with chloroquine. There was no reported history of
fever a day after treatment and no child subsequently
had raised axillary temperature.
Haematological response
The mean packed cell volume at enrolment of
children with early treatment failure was 27.1%.
These children were treated with sulfadoxine–
pyrimethamine and at day 14 the repeat packed cell
volume was 29.5% (a rise of 2.4%). The mean packed
cell volume of children with adequate clinical
response (success) at enrolment was 27.1% and their
repeat mean packed cell volume on day 14 was
27.2%. The mean changes in packed cell volume of
early treatment failures and adequate clinical re-
sponse groups were compared and the difference was
found to be statistically significant (Student’s t
test 9.8, P <0.001). The early treatment failure group
showed a significant improvement in their anaemic
status after treatment with sulfadoxine–pyrimetha-
mine (Table 2).
The anaemic status of children with late
treatment failure (day 7 and 14) did not improve
despite treatment with sulfadoxine–pyrimethamine.
This could have arisen because we were not able to
follow up the late treatment failure cases for long
enough after sulfadoxine–pyrimethamine treatment
to assess their haematological response.
Discussion
There are many anecdotal and published reports of
decreased chloroquine efficacy from some areas of
the United Republic of Tanzania. Countrywide
chloroquine sensitivity studies conducted by the
National Institute of Medical Research have demon-
strated varying degrees of resistance in vivo and in vitro
in the regions tested so far. The median in vivo
resistance rate in asymptomatic schoolchildren was
20% (6). However, the exact levels of chloroquine
efficacy, especially in urban areas where drug
pressure may be higher, remain unknown. This study
shows a treatment failure rate greater than 40%.
Reports from elsewhere in the United Republic of
Tanzania indicate a failure rate of 40–50% (7).
There are as yet no generally accepted guide-
lines for policy-makers considering a change in first-
line therapy for malaria. However, Schapira et al. (8)
affirm that, on the basis of maintaining effective
treatment at reasonable cost, a drug with a failure rate
of more than 25–35% should not be used as first-line
treatment for young children if a more suitable
alternative is available. Sudre et al. (9) argue that when
the prevalence of RIII resistance in young children is
greater than 14–31%, depending on compliance,
sulfadoxine–pyrimethamine is the most cost-effec-
tive treatment despite its 45% higher price. Bloland et
al. (3) propose that when 5–10% of cases are RIII
resistant, the duration of clinical improvement and
haematological recovery should be considered. Our
results suggest that haematological recovery is better
in children treated with sulfadoxine–pyrimethamine.
This is an important observation since malarial
anaemia is a major cause of morbidity and mortality
in malaria-endemic areas (10). The high treatment
failure rate seen with chloroquine and its low impact
on the anaemic status of children call for a change in
the official drug policy. Clearly, chloroquine is no
longer effective at decreasing malaria morbidity
among under-5-year-olds in the study area.
Sulfadoxine–pyrimethamine will be the prob-
able replacement for chloroquine in the United
Republic of Tanzania. However, there are already
reports of alarming levels of sulfadoxine–pyrimetha-
mine resistance in areas where it has routinely been
used (11). As a result, there will be a greater need for
close routine monitoring of antimalarial efficacy. We
believe that a 3-day follow-up to detect early
treatment failures can be incorporated into the
existing health system at the district level in the
United Republic of Tanzania. However, such a
follow-up period cannot provide data on haemato-
logical response, and therefore an early treatment
failure rate of 5–10% may warrant a 14-day follow-up
by research teams to confirm the extent of the
problem and make recommendations as appropriate.
Applicability of the WHO protocol
Our experience with the study protocol is positive
and the protocol is suitable for use in malaria-
endemic areas. The diagnosis of an acute malarial
Table 2. Temperature and parasitaemia profiles of children
after chloroquine treatment failure (n = 86)
Day 3 Day 7 Day 14
(n = 25) (n = 28) (n = 33)
No. with temperature
537.5 oC 17; 68a 20; 71 23; 70
Geometric mean
parasitaemia 7 5 829 5 807
density (per ml) (50–84 000)b (1 680–40 000) (1 200–51 600)
Mean packed cell
volume 27.1%c; 29.5%d 28.6%c; 28.1%d 28.6%c; 27.3%d
a Figures in italics are percentages.
b Figures in parentheses are the range.
c Packed cell volume at enrolment.
d Repeat packed cell volume on day 14 (all treatment failures with chloroquine were given
sulfadoxine–pyrimethamine).
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episode remains a controversial issue in community
surveys, especially whether to include children with a
reported history of fever in the absence of raised
axillary temperature. A history of fever reported by
the mother during the preceding 12 hours correlated
well with a malaria episode in this study, and we
suggest that it be incorporated in the inclusion
criteria.
Some statistical evidence suggested that the
treatment outcome depended on the level of baseline
parasitaemia. We suggest that the inclusion criterion
for parasite density be raised from 2000 to 5000
per ml. A combination of a history of fever in the
preceding 12 hours and a higher parasite density in
the inclusion criteria will guard against decreased
specificity resulting from children with a history of
fever only. In endemic areas during the peak
transmission season the criteria of a history of fever
and higher parasitaemia will permit recruitment of
more children. This will not have an impact on the
outcome of the study and will enable surveys to be
carried out more rapidly and with reduced costs.
Conclusions
We conclude from these results that there is a
relatively high rate of chloroquine treatment failure in
Dar es Salaam. It is not clear, however, how
widespread this problem is throughout the country
and a rapid assessment of this should be carried out
on a national scale using the approach described here.
Should the efficacy of chloroquine throughout the
United Republic of Tanzania prove to be as poor as it
is in Dar es Salaam, the ethics and rationale of
continuing to maintain chloroquine as the first-line
drug for the treatment of malaria must seriously be
questioned.
Our observations suggest that sulfadoxine–
pyrimethamine may be considered as a replacement
for chloroquine to treat uncomplicated malaria in Dar
es Salaam, but nationwide data on its current efficacy
in the United Republic of Tanzania are urgently
needed. In addition, a practical surveillance system
will need to be established, so that the alarm can be
raised in sufficient time when treatment failure
occurs in the future. The recent initiative, The East
African Network for Monitoring Antimalarial Treat-
ment, is a step in the right direction in this respect.
The WHO protocol for assessment of ther-
apeutic efficacy was found to be practical in our
hands but the inclusion criteria may require mod-
ification. n
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Re´sume´
Efficacite´ clinique actuelle de la chloroquine dans le traitement du paludisme
a` Plasmodium falciparum a` Dar-es-Salaam (Re´publique-Unie de Tanzanie)
Nous avons utilise´ un protocole the´rapeutique de l’OMS
relativement nouveau qui prend en compte la re´ponse
clinique, parasitologique et he´matologique aux anti-
palude´ens pour e´valuer l’efficacite´ the´rapeutique de la
chloroquine dans le traitement du paludisme sans
complications chez des enfants en bas aˆge (n = 200)
dans la zone urbaine de la ville de Dar-es-Salaam
(Re´publique-Unie de Tanzanie). On a constate´ un e´chec du
traitement chez 43% des enfants, et parmi eux, 12,5%
ont e´te´ conside´re´s comme des e´checs the´rapeutiques
pre´coces et ont rec¸u une dose unique de sulfadoxine-
pyrime´thamine. La fie`vre est tombe´e chez tous les enfants
traite´s par cette association et il n’y a pas eu d’e´chec
the´rapeutique au sens parasitologique. En outre, les
enfants traite´s par la sulfadoxine-pyrime´thamine ont
mieux re´cupe´re´ sur le plan he´matologique que ceux du
groupe dont l’infection avait ce´de´ a` la chloroquine.
La conclusion que nous tirons de ces re´sultats, c’est
que les infections palustres qui ne ce`dent pas a` la
chloroquine sont relativement fre´quentes a` Dar-es-
Salaam. On ne sait pas exactement, cependant, dans
quelle mesure le meˆme proble`me se pose sur l’ensemble du
territoire tanzanien et il serait donc indique´ de proce´der a`
une enqueˆte rapide a` l’e´chelle nationale. Si cette enqueˆte
montre que le traitement par la chloroquine donne dans
l’ensemble du pays des re´sultats aussi me´diocres qu’a` Dar-
es-Salaam, il faudra se poser la question de savoir s’il est
raisonnable et moralement justifie´ de continuer a`
conside´rer la chloroquine comme l’antipalude´en de
premie`re intention en Re´publique-Unie de Tanzanie.
Nos observations donnent a` penser qu’on pourrait
envisager de remplacer la chloroquine par l’association
sulfadoxine-pyrime´thamine pour traiter les cas de
paludisme sans complications a` Dar-es-Salaam. Toutefois,
il est urgent d’obtenir davantage de donne´es sur son
efficacite´ actuelle dans l’ensemble du territoire. En outre, il
faudra mettre en place un syste`me pratique de surveillance
de manie`re qu’a` l’avenir, on puisse traiter, en temps utile,
les cas d’e´chec the´rapeutique. Dans cette optique,
l’initiative, qui a e´te´ re´cemment prise en Afrique, de cre´er
un re´seau baptise´ East African Network for Monitoring
Antimalarial Treament, va dans le bon sens.
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Resumen
Eficacia clı´nica actual de la cloroquina en el tratamiento de las infecciones
por Plasmodium falciparum en las zonas urbanas de Dar-es-Salaam, Repu´blica Unida
de Tanzanı´a
Utilizamos el nuevo protocolo de la OMS en el que se
tienen en cuenta las respuestas clı´nica, parasitolo´gica y
hematolo´gica a los medicamentos antipalu´dicos para
determinar la eficacia de la cloroquina en el tratamiento
del paludismo no complicado en nin˜os de corta edad
(n = 200) en las zonas urbanas de Dar-es-Salaam,
Repu´blica Unida de Tanzanı´a. La cloroquina no surtio´
efecto en un 43% de los nin˜os; en el 12,5% de los casos
fracaso´ el tratamiento inicial y se administro´ una dosis
u´nica de sulfadoxina-pirimetamina (S-P). La fiebre
remitio´ en todos los nin˜os tratados con S-P, al igual
que la parasitemia. Adema´s, los nin˜os tratados con S-P
de esta manera presentaron una mejor recuperacio´n
hematolo´gica que el grupo sensible a la cloroquina.
Concluimos a partir de estos resultados que en la
poblacio´n de Dar-es-Salaam hay un nivel relativamente
alto de resistencia a la cloroquina. Sin embargo no esta´
claro si se trata de un problema generalizado en el paı´s,
por lo que convendrı´a realizar una evaluacio´n ra´pida a
escala nacional. Si la eficacia terape´utica de la cloroquina
en todo el paı´s resulta ser tan baja como en Dar-es-
Salaam, habra´ que replantearse la e´tica y la lo´gica del
mantenimiento de la cloroquina como medicamento
antipalu´dico de primera lı´nea en Tanzanı´a.
Nuestras observaciones indican que la combina-
cio´n sulfadoxina-pirimetamina puede considerarse una
alternativa a la cloroquina en el tratamiento del
paludismo no complicado; sin embargo, se necesitan
urgentemente ma´s datos a escala nacional sobre su
actual eficacia. Adema´s, habra´ que poner en marcha un
sistema pra´ctico de vigilancia, para que en el futuro se
pueda alertar prontamente de los casos de fracaso
terape´utico. En este sentido, la Red de A´frica Oriental
para la Vigilancia de los Tratamientos Antipalu´dicos,
iniciativa lanzada recientemente, es un paso en la
direccio´n correcta.
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